MedPath

Cell Therapy Weekly: FDA grants ODD for Retinal Gene Therapy - RegMedNet

FDA grants Fast Track designation to Abata Therapeutics' autologous Treg therapy for progressive MS, ABA-101. Orgenesis Inc. reports encouraging results from its CD19 CAR-T therapy trial for CD19+ acute lymphoblastic leukemia, with high response rates and low severe cytokine release syndrome incidence. Skyline Therapeutics' SKG1108, a gene therapy for retinitis pigmentosa, receives FDA Orphan Drug Designation.


Reference News

Cell Therapy Weekly: FDA grants ODD for Retinal Gene Therapy - RegMedNet

FDA grants Fast Track designation to Abata Therapeutics' autologous Treg therapy for progressive MS, ABA-101. Orgenesis Inc. reports encouraging results from its CD19 CAR-T therapy trial for CD19+ acute lymphoblastic leukemia, with high response rates and low severe cytokine release syndrome incidence. Skyline Therapeutics' SKG1108, a gene therapy for retinitis pigmentosa, receives FDA Orphan Drug Designation.

© Copyright 2025. All Rights Reserved by MedPath